TDP-43: The relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration

FEBS Journal

Volumn 278, Issue 19, 2011, Pages 3539-3549

  Baloh, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyotrophic lateral sclerosis; frontotemporal dementia; motor neuron disease; prion domain; protein aggregation; RNA metabolism

Indexed keywords

TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE ASSOCIATION; DISEASE MODEL; FRONTOTEMPORAL DEMENTIA; HUMAN; IN VITRO STUDY; MOLECULAR MODEL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PURIFICATION; PROTEIN RNA BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; DNA-BINDING PROTEINS; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; INCLUSION BODIES; NERVE DEGENERATION; RNA; UBIQUITIN;

ANIMALIA;

EID: 80052967905     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08256.x     Document Type: Review

References (87)

1. Skovronsky DM, Lee VM, &, Trojanowski JQ, (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1, 151-170.
2. Winklhofer KF, Tatzelt J, &, Haass C, (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27, 336-349. (Pubitemid 351161650)
3. Lomen-Hoerth C, (2004) Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 17, 337-341. (Pubitemid 38721154)
4. Leigh PN, Whitwell H, Garofalo O, Buller J, Swash M, Martin JE, Gallo JM, Weller RO, &, Anderton BH, (1991) Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain 114, 775-788.
5. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133. (Pubitemid 44547757)
6. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602-611. (Pubitemid 44708852)
7. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL III, Bigio EH, Caselli R, et al. (2008) TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 63, 535-538. (Pubitemid 351614720)
8. Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi H, Tsujino A, Ikeuchi T, Kakita A, et al. (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 63, 538-542. (Pubitemid 351614721)
9. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40, 572-574. (Pubitemid 351601218)
10. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, et al. (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol 7, 409-416.
11. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672. (Pubitemid 351432505)
12. Buratti E, &, Baralle FE, (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 13, 867-878. (Pubitemid 351594732)
13. Fiesel FC, &, Kahle PJ, (2011) TDP-43 and FUS/TLS: role in the pathophysiology of neurodegeneration processes. FEBS J 278, 3550-3568.
14. Kwong LK, Uryu K, Trojanowski JQ, &, Lee VM, (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16, 41-51. (Pubitemid 350308320)
15. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL III, Schneider JA, Grinberg LT, Halliday G, et al. (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114, 5-22. (Pubitemid 47029055)
16. Whitwell JL, Jack CR Jr, Parisi JE, Senjem ML, Knopman DS, Boeve BF, Rademakers R, Baker M, Petersen RC, Dickson DW, et al. (2010) Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology 75, 2212-2220.
17. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, Dearmond SJ, Miller BL, &, Seeley WW, (2010) TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 75, 2204-2211.
18. Armstrong RA, Ellis W, Hamilton RL, Mackenzie IR, Hedreen J, Gearing M, Montine T, Vonsattel JP, Head E, Lieberman AP, et al. (2010) Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm 117, 227-239.
19. Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK, Moberg PJ, Moore EM, Van Deerlin VM, Lee VM, et al. (2010) Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol 67, 1238-1250.
20. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, &, Pestronk A, (2008) TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 79, 1186-1189.
21. Olive M, Janue A, Moreno D, Gamez J, Torrejon-Escribano B, &, Ferrer I, (2009) TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 68, 262-273.
22. Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, &, Greenberg SA, (2009) Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40, 19-31.
23. He Y, &, Smith R, (2009) Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell Mol Life Sci 66, 1239-1256.
24. Ou SH, Wu F, Harrich D, Garcia-Martinez LF, &, Gaynor RB, (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 69, 3584-3596.
25. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, &, Baralle FE, (2001) Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 20, 1774-1784. (Pubitemid 32299413)
26. Wang HY, Wang IF, Bose J, &, Shen CK, (2004) Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83, 130-139. (Pubitemid 37518267)
27. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, &, Baralle FE, (2005) TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 280, 37572-37584. (Pubitemid 41642366)
28. Abhyankar MM, Urekar C, &, Reddi PP, (2007) A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function. J Biol Chem 282, 36143-36154.
29. Fuentealba RA, Udan M, Bell S, Wegorzewska I, Shao J, Diamond MI, Weihl CC, &, Baloh RH, (2010) Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem 285, 26304-26314.
30. Cushman M, Johnson BS, King OD, Gitler AD, &, Shorter J, (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123, 1191-1201.
31. Udan M, &, Baloh RH, (2011) Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 5, 1-5.
32. Wickner RB, Edskes HK, Roberts BT, Baxa U, Pierce MM, Ross ED, &, Brachmann A, (2004) Prions: proteins as genes and infectious entities. Genes Dev 18, 470-485. (Pubitemid 38372804)
33. Halfmann R, Alberti S, &, Lindquist S, (2010) Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol 20, 125-133.
34. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, &, Gitler AD, (2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 284, 20329-20339.
35. Chen AK, Lin RY, Hsieh EZ, Tu PH, Chen RP, Liao TY, Chen W, Wang CH, &, Huang JJ, (2010) Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J Am Chem Soc 132, 1186-1187.
36. Johnson BS, McCaffery JM, Lindquist S, &, Gitler AD, (2008) A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 105, 6439-6444. (Pubitemid 351758364)
37. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. (2010) Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075.
38. Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, &, Baralle FE, (2008) Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci 121, 3778-3785.
39. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, &, Lee VM, (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283, 13302-13309.
40. Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, &, Lee VM, (2009) Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem 284, 8516-8524.
41. Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, Lin WL, Tong J, Castanedes-Casey M, Ash P, et al. (2009) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 106, 7607-7612.
42. Nonaka T, Kametani F, Arai T, Akiyama H, &, Hasegawa M, (2009) Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 18, 3353-3364.
43. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, &, Finkbeiner S, (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30, 639-649.
44. Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, &, Link CD, (2010) Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet 19, 3206-3218.
45. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C, et al. (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 19, 671-683.
46. Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, et al. (2011) TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30, 277-288.
47. Buratti E, &, Baralle F, (2011) TDP-43: new aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease. FEBS J 278, 3530-3538.
48. Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, Herz J, Peng J, et al. (2011) Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 286, 1204-1215.
49. Thomas MG, Loschi M, Desbats MA, &, Boccaccio GL, (2011) RNA granules: the good, the bad and the ugly. Cell Signal 23, 324-334.
50. Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, Silani V, &, Ratti A, (2009) TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem 111, 1051-1061.
51. Freibaum BD, Chitta RK, High AA, &, Taylor JP, (2010) Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 9, 1104-1120.
52. Dewey CM, Cenik B, Sephton CF, Dries DR, Mayer P III, Good SK, Johnson BA, Herz J, &, Yu G, (2011) TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol 31, 1098-1108.
53. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, Vanderwyde T, Citro A, Mehta T, Zaarur N, McKee A, Bowser R, Sherman M, et al. (2010) Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS ONE 5, e13250.
54. Anderson P, &, Kedersha N, (2009) RNA granules: post-transcriptional and epigenetic modulators of gene expression. Nat Rev Mol Cell Biol 10, 430-436.
55. Strong MJ, &, Volkening K, (2011) TDP-43 and FUS/TLS: sending a complex message about messenger RNA in Amyotrophic Lateral Sclerosis. FEBS J.
56. Kiebler MA, &, Bassell GJ, (2006) Neuronal RNA granules: movers and makers. Neuron 51, 685-690. (Pubitemid 44374907)
57. Wang IF, Wu LS, Chang HY, &, Shen CK, (2008) TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 105, 797-806.
58. Buchan JR, &, Parker R, (2009) Eukaryotic stress granules: the ins and outs of translation. Mol Cell 36, 932-941.
59. Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA III, Fushimi K, &, Wu JY, (2010) A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A 107, 3169-3174.
60. Liachko NF, Guthrie CR, &, Kraemer BC, (2010) Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci 30, 16208-16219.
61. Laird AS, Van Hoecke A, De Muynck L, Timmers M, Van den Bosch L, Van Damme P, &, Robberecht W, (2010) Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 5, e13368.
62. Hanson KA, Kim SH, Wassarman DA, &, Tibbetts RS, (2010) Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS). J Biol Chem 285, 11068-11072.
63. Miguel L, Frebourg T, Campion D, &, Lecourtois M, (2010) Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol Dis 41, 398-406.
64. Voigt A, Herholz D, Fiesel FC, Kaur K, Muller D, Karsten P, Weber SS, Kahle PJ, Marquardt T, &, Schulz JB, (2010) TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS ONE 5, e12247.
65. Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, Tang W, Winton MJ, Neumann M, Trojanowski JQ, et al. (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30, 7729-7739.
66. Wegorzewska I, &, Baloh RH, (2010) TDP-43-based animal models of neurodegeneration: new insights into ALS pathology and pathophysiology. Neurodegener Dis.
67. Wegorzewska I, Bell S, Cairns NJ, Miller TM, &, Baloh RH, (2009) TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 106, 18809-18814.
68. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, &, Kumar-Singh S, (2010) TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 107, 3858-3863.
69. Xu YF, Gendron TF, Zhang YJ, Lin WL, D'Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, et al. (2010) Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci 30, 10851-10859.
70. Stallings NR, Puttaparthi K, Luther CM, Burns DK, &, Elliott JL, (2010) Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis 40, 404-414.
71. Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP, Fu WM, &, Shen CK, (2010) Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med 207, 1661-1673.
72. Zhou H, Huang C, Chen H, Wang D, Landel CP, Xia PY, Bowser R, Liu YJ, &, Xia XG, (2010) A transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet 6, e1000887.
73. Ashe KH, &, Zahs KR, (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66, 631-645.
74. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, Clark HB, Zoghbi HY, &, Orr HT, (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53. (Pubitemid 28458023)
75. Saudou F, Finkbeiner S, Devys D, &, Greenberg ME, (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
76. Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, Xie SX, Lee VM, &, Trojanowski JQ, (2008) Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol 65, 636-641. (Pubitemid 351679659)
77. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, et al. (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119, 1-4.
78. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al. (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 1184, 284-294. (Pubitemid 350160566)
79. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, &, Dickson DW, (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 61, 435-445. (Pubitemid 46878771)
80. King A, Sweeney F, Bodi I, Troakes C, Maekawa S, &, Al-Sarraj S, (2010) Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. Neuropathology 30, 408-419.
81. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Leverenz JB, et al. (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114, 221-229. (Pubitemid 47226148)
82. Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, et al. (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67, 555-564. (Pubitemid 351787082)
83. Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, Hasegawa M, Akiyama H, Sikkink S, Pickering-Brown S, et al. (2010) Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 120, 55-66.
84. Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, Yamazaki M, &, Oyanagi K, (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130, 1386-1394. (Pubitemid 47355958)
85. Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP, Galasko D, Lee VM, et al. (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115, 133-145. (Pubitemid 350238671)
86. Schwab C, Arai T, Hasegawa M, Yu S, &, McGeer PL, (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67, 1159-1165.
87. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, et al. (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69, 918-929.